Intravenous immunoglobulin (IVIg) dampens neuronal toll-like receptor-mediated responses in ischemia.

ABSTRACT:

Background

Ischemic stroke causes a high rate of deaths and permanent neurological damage in survivors. Ischemic stroke triggers the release of damage-associated molecular patterns (DAMPs) such as high-mobility group box 1 (HMGB1), which activate toll-like receptors (TLRs) and receptor for advanced glycation endproducts (RAGE) in the affected area, leading to an exaggerated inflammatory response and cell death. Both TLRs and RAGE are transmembrane pattern recognition receptors (PRRs) that have been shown to contribute to ischemic stroke-induced brain injury. Intravenous immunoglobulin (IVIg) preparations obtained by fractionating human blood plasma are increasingly being used as an effective therapeutic agent in the treatment of several inflammatory diseases. Its use as a potential

SUBMITTER: Lok KZ 

PROVIDER: S-EPMC4409750 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature